Your browser doesn't support javascript.
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres

Base de données
Les sujets
Type de document
Gamme d'année
1.
Clin Appl Thromb Hemost ; 29: 10760296221148477, 2023.
Article Dans Anglais | MEDLINE | ID: covidwho-2195100

Résumé

Coronavirus disease 2019 (COVID-19) affects the respiratory system of patients and is characterized by pneumonia with hypoxemia. Hospitalized patients and particularly those admitted to intensive care unit (ICU) may encounter a cascade of coagulopathies, which may lead to macrovessel thrombotic events such as pulmonary embolism (PE), deep vein thrombosis (DVT), or arterial thromboembolism (ATE). These events can result in serious life-threatening diseases including cerebrovascular stroke and myocardial infarction. Despite all available information about the incidence, prevention, and treatment of venous thromboembolism (VTE) among hospitalized patients, few data are available on the incidence of both symptomatic and subclinical VTE after discharge. Therefore, there is no precise suggestion or guideline for prophylaxis against VTE in post-discharge period, and some controversies exist over the current guidelines. In the present study, we aimed to review and summarize available literature upon incidence, prevention, diagnosis, and therapeutic approaches for VTE in COVID-19 patients. Also, the pathogenic mechanisms of VTE in infected individuals with COVID-19 were discussed.


Sujets)
COVID-19 , Embolie pulmonaire , Thromboembolisme veineux , Thrombose veineuse , Humains , COVID-19/complications , Thromboembolisme veineux/étiologie , Thromboembolisme veineux/prévention et contrôle , Thromboembolisme veineux/traitement médicamenteux , Thrombose veineuse/étiologie , Sortie du patient , Post-cure , Embolie pulmonaire/épidémiologie , Embolie pulmonaire/étiologie , Embolie pulmonaire/prévention et contrôle , Incidence , Anticoagulants/usage thérapeutique
2.
Exp Gerontol ; 154: 111507, 2021 10 15.
Article Dans Anglais | MEDLINE | ID: covidwho-1343214

Résumé

The emergence of Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) in late 2019 has been associated with a high rate of mortality and morbidity. It has been determined that the old population are not only at an increased risk for affliction with COVID-19 infection, but also atypical presentations, severe forms of the disease, and mortality are more common in this population. A plethora of mechanisms and risk factors contribute to the higher risk of infection in the old population. For instance, aging is associated with an increment in the expression of Angiotensin-Converting Enzyme-2 (ACE-2), the receptor for SARS-CoV-2 spike protein, which precipitates replication of the virus in the old population. On the other hand, immune dysregulation and changes in gut microbiota as a result of aging can contribute to the cytokine storm, one of the main indicators of disease severity. Decrement in sex steroids, especially in women, as well as growth hormone, both of which have crucial roles in immune regulation, is a key contributor to disease severity in old age. Senescence-associated oxidative stress and mitochondrial dysfunction in both pneumocytes and immune cells contribute to the severity of infection in an exacerbative manner. In addition, lifestyle-associated factors such as nutrition and physical activity, which are compromised in old age, are known as important factors in COVID-19 infection. Aging-associated comorbidities, especially cardiovascular diseases and diabetes mellitus, also put older adults at an increased risk of complications, and disease severity.


Sujets)
COVID-19 , Sujet âgé , Vieillissement , Prédisposition aux maladies , Femelle , Humains , Facteurs de risque , SARS-CoV-2 , Indice de gravité de la maladie , Glycoprotéine de spicule des coronavirus
SÉLECTION CITATIONS
Détails de la recherche